<p>瑞银集团在其最近向证券交易委员会提交的 13F 表格中表示，在第四季度将其在启迪医疗系统公司的股份减少了 12.1%。该基金在此期间出售了 56,407 股后，持有该公司 411,329 股股票。截至其最近向证券交易委员会提交的文件，瑞银集团持有的启迪医疗系统股份约占 1.42%，价值 37,937,000 美元。</p>
<ul>
<li>艾利 Lilly 股票上涨：GLP-1 Zepbound 目标睡眠呼吸暂停市场</li>
</ul>
<p>其他几家大型投资者最近也调整了对该公司的持股。Sanctuary Advisors LLC 在第四季度收购了价值 481,000 美元的启迪医疗系统新股份。Concurrent Investment Advisors LLC 在第四季度将其在启迪医疗系统的股份增加了 52.0%。Concurrent Investment Advisors LLC 现在持有 4,815 股该公司股票，价值 444,000 美元，此前在上个季度又购买了 1,647 股。M&amp;T Bank Corp 在第四季度收购了价值 85,871,000 美元的启迪医疗系统新股份。Universal Beteiligungs und Servicegesellschaft mbH 在第四季度将其在启迪医疗系统的股份增加了 990.1%。Universal Beteiligungs und Servicegesellschaft mbH 现在持有 38,404 股该公司股票，价值 3,542,000 美元，此前在此期间又购买了 34,881 股。最后，苏黎世州立银行在第四季度将其在启迪医疗系统的股份增加了 5.8%。苏黎世州立银行现在持有 9,265 股该公司股票，价值 855,000 美元，此前在上个季度又购买了 507 股。机构投资者持有该公司 94.91% 的股份。</p>
<h2>启迪医疗系统股票下跌 0.5%</h2>
<p>NYSE:INSP 的股票在周五开盘时为 45.48 美元。启迪医疗系统公司的 12 个月低点为 44.41 美元，12 个月高点为 161.88 美元。该股票的 50 日移动平均线为 56.01 美元，200 日移动平均线为 78.97 美元。该公司的市值为 13.1 亿美元，市盈率为 10.13，PEG 比率为 4.73，贝塔值为 0.83。</p>
<ul>
<li>启迪医疗上涨 15% 后突破，分析师称其为买入</li>
</ul>
<p>启迪医疗系统（NYSE:INSP - 获取免费报告）最后一次公布季度财报是在 5 月 4 日，周一。该公司报告季度每股收益为 0.10 美元，超出分析师共识预期的（0.28 美元）0.38 美元。启迪医疗系统的净利润率为 14.33%，股本回报率为 10.35%。该公司在本季度的收入为 2.0458 亿美元，而分析师预期为 2.0004 亿美元。在去年同期，该公司每股收益为 0.10 美元。启迪医疗系统的季度收入同比增长 1.6%。启迪医疗系统已将其 2026 财年的指导目标设定为 0.750-1.250 每股收益。股票研究分析师预计启迪医疗系统将在当前财年发布 0.91 的每股收益。</p>
<h2>分析师评级变动</h2>
<p>INSP 最近成为多份分析师报告的主题。美国银行在周二重申了对启迪医疗系统的 “中性” 评级，并设定了 53.00 美元的目标价。Zacks Research 在 4 月 14 日的研究报告中将启迪医疗系统的评级从 “强力买入” 下调至 “持有”。Piper Sandler 在周二将启迪医疗系统的评级从 “增持” 下调至 “中性”，并将其目标价从 85.00 美元下调至 55.00 美元。摩根大通在周二将启迪医疗系统的目标价从 67.00 美元下调至 54.00 美元，并对该公司设定了 “中性” 评级。最后，罗伯特·W·贝尔德在周二将启迪医疗系统的目标价从 63.00 美元下调至 50.00 美元，并对该股票设定了 “中性” 评级。四位股票研究分析师对该股票给予了买入评级，十五位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “持有”，平均目标价为 85.00 美元。</p>
<ul>
<li>小型股是否预示市场下跌？</li>
</ul>
<p><strong>查看我们最新的 INSP 股票报告</strong></p>
<h2>启迪医疗系统公司简介</h2>
<p>（免费报告）</p>
<p>启迪医疗系统公司是一家医疗技术公司，专注于用于治疗阻塞性睡眠呼吸暂停（OSA）的可植入神经刺激设备。该公司的旗舰产品，Inspire®系统，通过对舌下神经的定向刺激，保持睡眠期间气道通畅，为对持续正压呼吸机（CPAP）设备不耐受或管理不当的患者提供了一种替代疗法。</p>
<p>Inspire 系统包括一个可植入的脉冲发生器，一个监测呼吸模式的传感导线，以及一个激活舌下神经的刺激导线。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过启迪医疗系统</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元于启迪医疗系统吗？</h2>
<p>在考虑启迪医疗系统之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而启迪医疗系统并不在名单上。</p>
<p>尽管启迪医疗目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

启迪医疗

瑞银集团

<p>瑞银集团（UBS Group AG）已将其在启迪医疗（Inspire Medical Systems, Inc.）的持股比例降低了 12.1%，在第四季度出售了 56,407 股，剩余持股为 411,329 股，估值约为 3,794 万美元。其他机构投资者也对其持股进行了调整。启迪医疗的股票开盘价为 45.48 美元，下跌 0.5%，市值为 13.1 亿美元。该公司报告的季度每股收益（EPS）为 0.10 美元，超出预期，并已将 2026 财年的指导目标设定为 0.750-1.250 的每股收益。分析师对该股票的评级意见不一，普遍评级为 “持有”，平均目标价为 85.00 美元</p>

<p>UBS Group AG reduced its position in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 12.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 411,329 shares of the company's stock after selling 56,407 shares during the period. UBS Group AG owned about 1.42% of Inspire Medical Systems worth $37,937,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>瑞银集团在其最近向证券交易委员会提交的 13F 表格中表示，在第四季度将其在启迪医疗系统公司的股份减少了 12.1%。该基金在此期间出售了 56,407 股后，持有该公司 411,329 股股票。截至其最近向证券交易委员会提交的文件，瑞银集团持有的启迪医疗系统股份约占 1.42%，价值 37,937,000 美元。</p>
</div><ul>
<li>Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market</li>
</ul>
<div class="lb-trans"><ul>
<li>艾利 Lilly 股票上涨：GLP-1 Zepbound 目标睡眠呼吸暂停市场</li>
</ul>
</div><p>Several other large investors have also recently modified their holdings of the business. Sanctuary Advisors LLC acquired a new stake in Inspire Medical Systems in the fourth quarter valued at $481,000. Concurrent Investment Advisors LLC boosted its stake in shares of Inspire Medical Systems by 52.0% in the 4th quarter. Concurrent Investment Advisors LLC now owns 4,815 shares of the company's stock valued at $444,000 after purchasing an additional 1,647 shares during the last quarter. M&amp;T Bank Corp bought a new stake in shares of Inspire Medical Systems in the 4th quarter valued at $85,871,000. Universal Beteiligungs und Servicegesellschaft mbH increased its position in shares of Inspire Medical Systems by 990.1% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 38,404 shares of the company's stock worth $3,542,000 after buying an additional 34,881 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Inspire Medical Systems by 5.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,265 shares of the company's stock worth $855,000 after buying an additional 507 shares during the last quarter. Institutional investors own 94.91% of the company's stock.</p>
<div class="lb-trans"><p>其他几家大型投资者最近也调整了对该公司的持股。Sanctuary Advisors LLC 在第四季度收购了价值 481,000 美元的启迪医疗系统新股份。Concurrent Investment Advisors LLC 在第四季度将其在启迪医疗系统的股份增加了 52.0%。Concurrent Investment Advisors LLC 现在持有 4,815 股该公司股票，价值 444,000 美元，此前在上个季度又购买了 1,647 股。M&amp;T Bank Corp 在第四季度收购了价值 85,871,000 美元的启迪医疗系统新股份。Universal Beteiligungs und Servicegesellschaft mbH 在第四季度将其在启迪医疗系统的股份增加了 990.1%。Universal Beteiligungs und Servicegesellschaft mbH 现在持有 38,404 股该公司股票，价值 3,542,000 美元，此前在此期间又购买了 34,881 股。最后，苏黎世州立银行在第四季度将其在启迪医疗系统的股份增加了 5.8%。苏黎世州立银行现在持有 9,265 股该公司股票，价值 855,000 美元，此前在上个季度又购买了 507 股。机构投资者持有该公司 94.91% 的股份。</p>
</div><h2>Inspire Medical Systems Stock Down 0.5%</h2>
<div class="lb-trans"><h2>启迪医疗系统股票下跌 0.5%</h2>
</div><p>Shares of NYSE:INSP opened at $45.48 on Friday. Inspire Medical Systems, Inc. has a twelve month low of $44.41 and a twelve month high of $161.88. The stock's 50 day moving average is $56.01 and its 200-day moving average is $78.97. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of 10.13, a PEG ratio of 4.73 and a beta of 0.83.</p>
<div class="lb-trans"><p>NYSE:INSP 的股票在周五开盘时为 45.48 美元。启迪医疗系统公司的 12 个月低点为 44.41 美元，12 个月高点为 161.88 美元。该股票的 50 日移动平均线为 56.01 美元，200 日移动平均线为 78.97 美元。该公司的市值为 13.1 亿美元，市盈率为 10.13，PEG 比率为 4.73，贝塔值为 0.83。</p>
</div><ul>
<li>Inspire Medical Up 15% After Breakout, Analysts Say It's A Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>启迪医疗上涨 15% 后突破，分析师称其为买入</li>
</ul>
</div><p>Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its quarterly earnings results on Monday, May 4th. The company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The business had revenue of $204.58 million during the quarter, compared to analyst estimates of $200.04 million. During the same quarter in the previous year, the business posted $0.10 EPS. Inspire Medical Systems's quarterly revenue was up 1.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. Equities research analysts anticipate that Inspire Medical Systems, Inc. will post 0.91 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>启迪医疗系统（NYSE:INSP - 获取免费报告）最后一次公布季度财报是在 5 月 4 日，周一。该公司报告季度每股收益为 0.10 美元，超出分析师共识预期的（0.28 美元）0.38 美元。启迪医疗系统的净利润率为 14.33%，股本回报率为 10.35%。该公司在本季度的收入为 2.0458 亿美元，而分析师预期为 2.0004 亿美元。在去年同期，该公司每股收益为 0.10 美元。启迪医疗系统的季度收入同比增长 1.6%。启迪医疗系统已将其 2026 财年的指导目标设定为 0.750-1.250 每股收益。股票研究分析师预计启迪医疗系统将在当前财年发布 0.91 的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>INSP has been the subject of a number of recent analyst reports. Bank of America reiterated a &#34;neutral&#34; rating and set a $53.00 price target on shares of Inspire Medical Systems in a report on Tuesday. Zacks Research lowered Inspire Medical Systems from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, April 14th. Piper Sandler downgraded Inspire Medical Systems from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating and lowered their target price for the stock from $85.00 to $55.00 in a report on Tuesday. JPMorgan Chase &amp; Co. lowered their price objective on shares of Inspire Medical Systems from $67.00 to $54.00 and set a &#34;neutral&#34; rating for the company in a research note on Tuesday. Finally, Robert W. Baird dropped their target price on shares of Inspire Medical Systems from $63.00 to $50.00 and set a &#34;neutral&#34; rating on the stock in a research report on Tuesday. Four equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Hold&#34; and an average target price of $85.00.</p>
<div class="lb-trans"><p>INSP 最近成为多份分析师报告的主题。美国银行在周二重申了对启迪医疗系统的 “中性” 评级，并设定了 53.00 美元的目标价。Zacks Research 在 4 月 14 日的研究报告中将启迪医疗系统的评级从 “强力买入” 下调至 “持有”。Piper Sandler 在周二将启迪医疗系统的评级从 “增持” 下调至 “中性”，并将其目标价从 85.00 美元下调至 55.00 美元。摩根大通在周二将启迪医疗系统的目标价从 67.00 美元下调至 54.00 美元，并对该公司设定了 “中性” 评级。最后，罗伯特·W·贝尔德在周二将启迪医疗系统的目标价从 63.00 美元下调至 50.00 美元，并对该股票设定了 “中性” 评级。四位股票研究分析师对该股票给予了买入评级，十五位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “持有”，平均目标价为 85.00 美元。</p>
</div><ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股是否预示市场下跌？</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Report on INSP</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 INSP 股票报告</strong></p>
</div><h2>Inspire Medical Systems Company Profile</h2>
<div class="lb-trans"><h2>启迪医疗系统公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.</p>
<div class="lb-trans"><p>启迪医疗系统公司是一家医疗技术公司，专注于用于治疗阻塞性睡眠呼吸暂停（OSA）的可植入神经刺激设备。该公司的旗舰产品，Inspire®系统，通过对舌下神经的定向刺激，保持睡眠期间气道通畅，为对持续正压呼吸机（CPAP）设备不耐受或管理不当的患者提供了一种替代疗法。</p>
</div><p>The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.</p>
<div class="lb-trans"><p>Inspire 系统包括一个可植入的脉冲发生器，一个监测呼吸模式的传感导线，以及一个激活舌下神经的刺激导线。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Inspire Medical Systems</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过启迪医疗系统</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=INSP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Inspire Medical Systems Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元于启迪医疗系统吗？</h2>
</div><p>Before you consider Inspire Medical Systems, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑启迪医疗系统之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inspire Medical Systems wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而启迪医疗系统并不在名单上。</p>
</div><p>While Inspire Medical Systems currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管启迪医疗目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

瑞银集团出售了 56,407 股启迪医疗系统公司（Inspire Medical Systems, Inc.）的股票 $INSP